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Short title:  Congenital Chagas disease in Bolivia 
 
Summary:  Congenital Trypanosoma cruzi transmission is now estimated to account for 22% of 
new infections.  Though the proportion of T. cruzi infected infants with clinical signs has fallen 
from the 1990s, but symptomatic congenital Chagas disease still represents a significant, albeit 
increasingly challenging to detect, public health problem.   
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Abstract  
Background: Congenital Trypanosoma cruzi transmission is now estimated to account for 22% 
of new infections, representing a significant public health problem across Latin America and 
internationally. Treatment during infancy is highly efficacious and well tolerated, but current 
assays for early detection fail to detect >50% of infected neonates and 9 month follow-up is low.  
Methods: Women presenting for delivery in two urban hospitals in Santa Cruz department, 
Bolivia were screened by rapid test. Specimens from infants of infected women were tested by 
microscopy (micromethod), quantitative PCR (qPCR) and IgM trypomastigote excreted-secreted 
antigen (TESA)-blots at birth and 1 month, and by IgG serology at 6 and 9 months.  
Results: Among 487 infants of 476 seropositive women, congenital T. cruzi infection was 
detected in 38 infants of 35 mothers (7.8%).   In cord blood, qPCR, TESA-blot and micromethod 
sensitivities/specificities were 68.6%/99.1%, 58.3%/99.1% and 16.7%/100%, respectively. When 
birth and 1 month results were combined, cumulative sensitivities reached 84.2%, 73.7% and 
34.2%, respectively. Low birth weight and/or respiratory distress were reported in 11 (29%) 
infected infants.  Infants with clinical signs had higher parasite loads and were significantly more 
likely to be detected by micromethod. 
Conclusions: The proportion of T. cruzi infected infants with clinical signs has fallen from the 
1990s, but symptomatic congenital Chagas disease still represents a significant, albeit 
increasingly challenging to detect, public health problem.  Molecular methods could facilitate 
earlier diagnosis and circumvent loss to follow-up but remain logistically and economically 
prohibitive for routine screening in resource-limited settings.  
 
Keywords congenital, Chagas disease, Trypanosoma cruzi, Bolivia, diagnostics 
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Introduction 
 Successful regional control initiatives have dramatically decreased the prevalence of 
Chagas disease from an estimated 18 million in 1990 to <6 million infections in 2015 [1].  With 
the marked decline in vector-borne transmission, congenital infections are now estimated to 
account for 22% of new cases [1]. The Bolivian Gran Chaco region has the highest Trypanosoma 
cruzi seroprevalence in the world; the majority of adults are infected, including 20-50% of 
women of child-bearing age [2].  Women infected as children remain at risk of vertical 
transmission throughout their child-bearing years, and congenitally-infected women can transmit 
to their children, thus sustaining the cycle across generations in the absence of the vector [3]. 
Without treatment, 20-30% of chronic T. cruzi infections progress to irreversible, potentially 
fatal cardiomyopathy and/or gastrointestinal disease; congenital infection is assumed to carry the 
same long-term risk [4]. 
 Trypanocidal chemotherapy during infancy is highly efficacious and well tolerated [5].  
However, many biological and operational issues complicate timely diagnosis and treatment of 
congenital Chagas disease.  Infected infants are asymptomatic or have non-specific signs, so 
detection requires laboratory screening.  In endemic regions, detection relies on a complex, 
multi-step algorithm, beginning with maternal serological screening and followed by testing of 
multiple infant specimens over 6 to 12 months. Early specimens are evaluated by microscopy in 
concentrated cord or peripheral blood collected in microhematocrit tubes (often referred to as 
“micromethod”) [6, 7]. For infants not diagnosed early, one or more specimens must be tested by 
IgG serology after 6-9 months, once maternal antibodies have cleared [3]. The micromethod, 
even when optimally executed, fails to detect more than half of infections [8, 9], and in control 
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programs, fewer than 20% of infants complete the 9 months of follow-up needed for unequivocal 
diagnosis [10, 11].  
 Historically, congenital Chagas disease has been associated with high morbidity and 
mortality rates, ranging from low birth weight, prematurity and low Apgar scores to 
meningoencephalitis, anaemia, thrombocytopenia and respiratory distress syndrome [12, 13].  
More recent cohort data report a decline in severe congenital cases [12]. Although factors driving 
improvements in clinical outcome remain largely unknown, secular trends in nutrition and 
prenatal care may play a role [12].  Higher levels of neonatal parasitaemia have been reported to 
be associated with more severe disease [14].   
We conducted a cohort study of pregnant women and their infants in two hospitals in 
Bolivia from 2010 to 2014 [2].  The objectives of the current analysis were to evaluate the 
performance of diagnostic tests applicable early in infancy and to describe the clinical 
manifestations of congenital Chagas disease in an endemic setting. 
 
Materials and methods 
Ethics statement 
The protocol was approved by the Institutional Review Boards of Hospital Universitario Japones 
(HUJ) (protocol #006), Universidad Catolica Boliviana, Universidad Peruana Cayetano Heredia 
(UPCH) (protocol #56907), Asociación Benéfica Proyectos en Informática, Salud, Medicina y 
Agricultura (AB PRISMA), Centers for Disease Control and Prevention (protocol #5829) and 
Johns Hopkins Bloomberg School of Public Health (IRB #2644). Approval to perform secondary 
data analyses was granted by the London School of Hygiene and Tropical Medicine (LSHTM) 
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(#5483). All study women provided written informed consent for their own and their infants’ 
participation.  
Study population 
The study was conducted in Hospital Japones in Santa Cruz de la Sierra (population ~1.7 
million), and the Municipal Hospital of Camiri, (population ~30,000), 300 km south of Santa 
Cruz. Vector-borne T. cruzi transmission is absent in the most urbanized zones, but many rural 
migrants have moved to the cities in recent decades.  In addition, many women living in villages 
with continued vector-borne transmission give birth in the hospital in Camiri. Trained study 
nurses enrolled women presenting for delivery, obtained informed consent and collected 
demographic, clinical and epidemiological data. 
Diagnosis of maternal T. cruzi infection 
Maternal venous blood was collected in serum separator tubes, centrifuged and screened by two 
rapid tests, TrypanosomaDetect or Chagas Detect Plus (InBios, Seattle, WA) and PolyChaco 
indirect hemagglutination assay (IHA; Lemos Laboratories, Santiago del Estero, Argentina) at a 
single dilution of 1:16.  Sera were subsequently tested by IHA with multiple dilutions and 
Chagatest lysate ELISA, with Recombinante 3.0 ELISA to resolve discordant results (both 
ELISAs from Wiener Laboratories, Rosario, Argentina). Confirmed infection required positive 
results by two or more tests [31].  
Diagnosis of congenital T. cruzi infection 
A study nurse attended the delivery of each rapid test-positive woman.  Cord blood and umbilical 
tissue were collected at birth; infant venous blood was collected at 30, 180 and 270 days after 
birth.  Infant specimens were evaluated using three techniques: micromethod, IgM 
trypomastigote excreted-secreted antigens (TESA)-blots and qPCR [6-8].  For micromethod, 
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blood was aliquoted in 4-6 heparinized microhematocrit tubes, sealed, and processed by 
centrifugation (12,000 rpm for 7 minutes) followed by microscopic examination.  Six and 9 
month specimens were tested by the same IgG serological assays as maternal specimens. 
Parasite load was measured by quantitative real time polymerase chain reaction (qPCR) 
in 500 l blood specimens and 25 mg specimens of umbilical tissue. DNA was extracted using 
standard phenol-chloroform for specimens processed prior to January 2012 [15] and afterward 
using an automated Qiacube system and Qiagen DNA extraction kits (Qiagen, Hilden, 
Germany). qPCR was conducted according to published methods, using primers Cruzi 1 (5'–
ASTCGGCTGATCGTTTTCGA–3') and Cruzi 2 (5'–AATTCCTCCAAGCAGCGGATA–3') to 
amplify a 166 bp fragment of nuclear satellite DNA [8, 16]. The probe Cruzi 3 (5'–
CACACACTGGACACCAA–3') was labeled with 5´FAM (6 – carboxyfluorescein) and 3´MGB 
(minor groove binder). TaqMan Human RNase-P detection reagent (Applied Biosystems) was 
included as an internal control; results were considered valid only if the internal control was 
efficiently amplified. A non-template negative control was included in each PCR run. PCR 
standard curves were generated by inoculating a blood clot specimen with 1 x 10
6
 T. cruzi Y 
strain trypomastigotes, followed by DNA extraction and serial dilutions. The detection limit was 
determined to be 1 parasite/ml. A positive result was defined by a Ct value below the Ct value of 
the detection limit standard, which fell consistently between 37 and 38 cycles. Parasite loads in 
individual specimens were calculated based on the standard curve included in each batch run.  
 IgM Western blots were performed on sera from cord and 30 day blood, using 
trypomastigote excreted-secreted antigens (TESA-blots) [17].  Ladder-like bands at 130-200 kDa 
on IgM TESA-blots demonstrate antibodies to Shed Acute Phase Antigens (SAPA), indicating 
acute or congenital infection.  Bands below 95 kDa are considered non-specific. Infant sera from 
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the 180 and 270 day specimens were analyzed by IHA and ELISA, as previously described for 
confirmation of T. cruzi infection.   
 We considered an infant to have unequivocal congenital infection if he or she had 
positive results by micromethod, positive PCR in two specimens collected at different time 
points, or positive PCR plus positive IgM TESA-blot. Infants were also considered infected 
based on positive serology at 6 months with IHA titer >=1:128 and ELISA absorbance value > 
0.7 or positive serology at 9 months by IHA and ELISA with cut-offs based on the 
manufacturer’s specifications.  In our earlier study, we found that 78% of uninfected infants had 
positive results by Chagatest ELISA at 6 months but all absorbance values were <0.7 [8].  
Neonatologists managed infected infants in compliance with the Bolivian National Control 
Program guidelines, which recommends antitrypanosomal treatment based on positive results by 
microhematocrit or serology at 6 or 9 months [7]. 
Data analysis 
Data analyses were conducted in STATA/SE 13.1 and SAS 9.0.   Performance characteristics of 
diagnostic tests were calculated with binomial 95% confidence intervals following standard 
statistical methods.  The significance of differences in categorical variables was tested using Chi 
square or Fishers exact test, depending on expected cell counts. Significance testing for 
continuous variables used the Wilcoxon two sample test with normal approximation.  
Multivariable models were constructed using forward stepwise logistical regression, testing 
variables with P<0.10 in univariate analyses. 
Results 
T. cruzi infection was confirmed in 476 (25.7%) of 1851 women screened; 465 infected women 
delivered singletons and 11 had twin births, yielding 487 infants at risk of infection.  Congenital 
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T. cruzi infection was diagnosed in 38 infants of 35 mothers, including three sets of concordantly 
infected twins (7.8% of at risk infants) (Table 1).  Of the 38 infected infants, 32 (84.2%) were 
detected by qPCR in the first month of life; of these, 28 also had positive results by TESA-blot 
and 13 by micromethod in one of the early specimens.  
Thirteen babies presented borderline or low PCR loads in a single specimen (Table S1).  
Four of these infants had infection ruled out based on negative serology at 6 or 9 months, while 
the other 9 were lost to follow-up, despite multiple contact attempts.  Of the 13 specimens with 
definite or possible false positive PCR results, 4 were processed on a single day in 2012 and 6 on 
a single day in 2014, suggesting potential laboratory contamination events.  Four babies were 
treated by a hospital neonatologist based on positive IHA at 6 months; their ELISA results were 
negative in 3 cases and showed low positive absorbance in the fourth. The National Control 
Program recommends treatment based on IHA titers of 1:128 or higher and positive ELISA at 6 
months [9], but ELISA is not routinely conducted in this hospital.   
Test performance characteristics were calculated for the 491 infants of seropositive 
mothers (Table 2).  The 17 infants in Table S1 were counted as uninfected for these calculations.  
Quantitative PCR, TESA-blot and micromethod displayed sensitivities of 68.6%, 58.3% and 
16.7% in cord blood, and 73.1%, 54.8% and 25.9%, in 1 month specimens, respectively. The 
sensitivity of qPCR in umbilical tissue was 69.7%. When birth and 1 month results were 
combined, cumulative sensitivities reached 84.2%, 73.7% and 34.2% for qPCR, TESA-blot and 
micromethod, respectively.   All assays had high specificity (Table 2).  
Eleven (28.9%) infected infants showed one or more signs of illness; 7 (63.6%) had 2 or 
more signs (Table S2).  Infected infants were significantly more likely to have birth weight < 
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2500 grams, respiratory distress, appear premature on physical examination, and/or be 
hospitalized at birth (Table 3).  All congenital infection and clinically manifest infection were 
both associated with younger maternal age.  In multivariable regression models, the odds of low 
birth weight were significantly higher for twins and T. cruzi infected infants (odds ratio (OR) and 
95% confidence intervals (CI) 11.4 [4.5, 29.1 and 2.7 [1.1, 6.8] respectively).   Similar results 
were found for all clinical illness (OR 7.1 [2.8, 17.6] and 2.5 [1.1, 5.8] for twins and congenital 
T. cruzi infection, respectively).  Many of the key variables (low birthweight, twin birth, 
respiratory distress, hospitalization) were significantly correlated with each other.   
Infected infants with clinical signs had significantly higher parasite loads in cord blood 
and umbilical cord tissue.  Among ill infants, the cumulative sensitivity of micromethod in cord 
and 1 month blood was 63.4%, compared to 22.2% among their asymptomatic counterparts 
(Table 4).  Positive results by qPCR or TESA-blot were not associated with clinical 
presentations.  
Discussion 
Regional Chagas disease control initiatives have achieved remarkable success over the past 25 
years, but several challenges remain [18].  Improved tools, or novel combinations of existing 
interventions, will be needed to achieve further reductions in incidence [19, 20].  Accurate early 
detection and treatment of congenital T. cruzi infection are crucial to this effort.  Treatment in 
infancy results in high cure rates and few side effects, but based on the low sensitivity of the 
micromethod and poor follow-up rates, more than half of infected infants go unrecognized in 
current programs [8, 10, 11].  Even in our study, with dedicated study nurses conducting active 
searches, 6 infected infants whose conventional testing was negative were lost to follow-up and 
never treated.   
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In our study, nearly one-third of infected neonates presented with signs attributable to 
congenital Chagas disease, but none were severely ill. Our data place this cohort of infants on a 
continuum with previous reports: the proportion of symptomatic congenital infections has 
continued to fall, from 55% of infants born in 1992-1994 and 45% in 1999-2001 [12], to 29% in 
our study in 2010-2014. Some of this decline is likely attributable to improvements in prenatal 
care and nutrition in Bolivia; the rate of low birth weight also declined in infants of uninfected 
mothers [12]. Other factors responsible for these changes are unknown.  Consistent with other 
studies, symptomatic infants had significantly higher parasite loads than asymptomatic infants 
[14, 21]. The higher sensitivity of the micromethod in sick infants compared to asymptomatic 
ones is the direct result of these higher parasite burdens.  Most recent studies have not included 
clinical data [21, 22], or have described all infected infants as asymptomatic [8, 23]; however, 
the lack of findings may reflect the small numbers of infected infants in most studies (usually 
<10).  A recent large study included 125 infected infants, but did not report clinical status data 
[24].  Our data demonstrate that symptomatic congenital Chagas disease has not disappeared and 
represents a significant unrecognized public health problem. 
We evaluated the operational performance and feasibility of three diagnostic techniques 
for detection of congenital Chagas disease in the first month of life. The micromethod, the only 
widely available test for this purpose, demonstrated low sensitivity. Specimen quality differed 
depending on the time between collection and processing; for example, if the birth occurred 
during the evening or night, microscopic examination was delayed until the following day, when 
trypomastigotes were no longer motile and were less likely to be detected.  However, the 
micromethod has the important advantage of affording unequivocal diagnosis, particularly of 
symptomatic infants, enabling the initiation of immediate treatment before mother and child left 
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the maternity ward. For this reason, the micromethod remains a valuable tool, and it would be 
premature to abandon it before routine access to more sophisticated, sensitive molecular assays 
can be assured.  
The most sensitive technique was qPCR, which has emerged as a promising diagnostic 
test, particularly for infections with parasite burdens below the detection limit of microscopy 
[25]. Nevertheless, multiple infant specimens were still needed to achieve optimal detection.  In 
addition to the considerable equipment and expertise requirements, rigorous quality control is 
essential for molecular results to be reliable. Some of our apparent false positive results may 
have been due to transplacental transfer and transient persistence of maternal parasite DNA, as 
described previously [8, 26]. However, the temporal clustering of 10 of the 13 positive results 
suggests specimen contamination as a more parsimonious explanation, and emphasizes the 
difficulties of sustaining quality control even in a research laboratory, let alone a large-scale 
surveillance program.  
Of the three diagnostic tests under evaluation, IgM-TESA blots represented a promising 
tool with intermediate characteristics [17].  Levels of sensitivity were higher than micromethod 
and this technique relies on infrastructure readily available for other serological diagnosis.  
However, blot strips fade quickly over time and must be interpreted immediately, bands can be 
ambiguous with imperfect reproducibility for a given specimen, and strips need to be produced 
in-house, raising issues of standardization between batches and laboratories.  Maintaining 
reliable, routine TESA-blot testing in Bolivia proved challenging; the results reported here were 
generated in our Lima research laboratory.  Adaptation to a more field-friendly format such as an 
ELISA would greatly facilitate wider use of IgM TESA-blot as an early diagnostic test for 
congenital Chagas disease. 
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Conventional serological diagnosis has the major disadvantage of delay: early treatment 
is preferable and programmatic loss to follow-up at 9 months reaches 80% [10, 11].  Negative 
results at 6 months allow shortened follow-up for some infants, but most are likely to need a 
specimen at 9 months to effectively rule out infection [8].  As our data show, decisions based on 
the 6 month results run the risk of exposing uninfected infants to unnecessary treatment.  Our 
follow-up rate was close to 70% while we had full-time research staff regularly tracking study 
participants, but this dropped to 30% once research staff time was cut back, a rate similar to that 
achieved by regional screening programs [10, 11].  An unexpected difficulty resulted from the 
fact that Bolivian cell phone numbers are terminated if not recharged at least every 60 days.  
Thus, many women were unreachable because their number at the time of delivery was no longer 
in effect when 6 and 9 month follow-up visits were due.  Mobile health initiatives have reported 
encouraging results in Argentina [27], but are unlikely to achieve high success rates in Bolivia 
when phone numbers change so frequently.   
Maintaining high screening program effectiveness is challenging in the face of the current 
multi-step algorithm.  The Chagas Detect Plus, used in this study for maternal screening, showed 
excellent performance in both serum and whole blood in evaluations in Bolivia [28], and was 
recently cleared for diagnostic use by the US Food and Drug Administration.  Such point-of-care 
tests facilitate the identification of mothers at risk of transmission to their infants.  The critical 
unmet need is for a field-friendly test for early detection of congenital infection. The ‘ideal’ 
assay would have high sensitivity in a single specimen, preferably at birth, and yield definitive 
results within a few hours to begin timely treatment and prevent loss to follow-up. A novel 
experimental technique based on concentration and detection of T. cruzi antigens in neonatal 
urine using nanoparticles may represent a viable, non-invasive alternative, if it can be adapted for 
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use in the field [29].  Much progress has been achieved in the control of Chagas disease; 
however, to sustain and build upon these successes, congenital Chagas disease screening 
strategies will require both diagnostic and programmatic improvements [10]. 
 
 
  
15 
 
NOTES: 
Acknowledgments: Members of the Working Group on Chagas disease in Bolivia and Peru 
include Lisbeth Ferrufino, Sara Quispe, Edith Hinojosa, Margot Ramirez, Eliana Saenza, Jorge 
Luis Flores-Franco, Janet Acosta, Maribel Suxo, Hilsen Roncales, Fernando Ramirez, Nazaret 
Bozo Escalera, Celia Espinoza, and Janet Vizcarra.  We are grateful to the nurses and physicians 
of the obstetrical services of Hospital Japones and Hospital Municipal Camiri for their 
collaboration and their dedication to the welfare of the women and infants of Santa Cruz 
Department. 
Disclaimer.  The funding sources had no role in the study design, collection, analysis and 
interpretation of the data, preparation of the manuscript, or the decision to submit for publication.  
Financial support: This work was supported by NIH R01-AI087776 and NIH Global Research 
Training Grant D43 TW006581.  LAM was supported by a Biotechnology and Biological 
Sciences Research Council doctoral training grant, the Dr. Gordon Smith Travelling Fellowship 
and a small grant from the Royal Society of Tropical Medicine and Hygiene.  
Potential Conflicts of interest: All authors: no potential conflicts of interest.  
 
  
16 
 
References 
1. World Health Organization. Chagas disease in Latin America: an epidemiological update 
based on 2010 estimates. Weekly Epidemiological Record 2015;90:33-44. 
2. Kaplinski M, Jois M, Galdos-Cardenas G, et al. Sustained domestic vector exposure is 
associated with increased Chagas cardiomyopathy risk but decreased parasitemia and 
congenital transmission risk among young women in Bolivia. Clin Infect Dis 2015 Sep 
15;61(6):918-26. 
3. Oliveira I, Torrico F, Munoz J, Gascon J. Congenital transmission of Chagas disease: a 
clinical approach. Expert Rev Anti Infect Ther 2010 Aug;8(8):945-56. 
4. Bern C. Chagas' Disease. N Engl J Med 2015 Jul 30;373(5):456-66. 
5. Chippaux JP, Salas-Clavijo AN, Postigo JR, Schneider D, Santalla JA, Brutus L. 
Evaluation of compliance to congenital Chagas disease treatment: results of a randomised 
trial in Bolivia. Trans R Soc Trop Med Hyg 2013 Jan;107(1):1-7. 
6. Freilij H, Muller L, Gonzalez Cappa SM. Direct micromethod for diagnosis of acute and 
congenital Chagas' disease. J Clin Microbiol 1983 Aug;18(2):327-30. 
7. Programa Nacional de Control de Chagas. Chagas Congénito: Estrategias de Diagnóstico 
y Control. 2nd ed: Digital Dreams, Cochabamba, Bolivia, 2007:1-89. 
8. Bern C, Verastegui M, Gilman RH, et al. Congenital Trypanosoma cruzi transmission in 
Santa Cruz, Bolivia. Clin Infect Dis 2009 Dec 1;49(11):1667-74. 
9. Mora MC, Sanchez Negrette O, Marco D, et al. Early diagnosis of congenital 
Trypanosoma cruzi infection using PCR, hemoculture, and capillary concentration, as 
compared with delayed serology. J Parasitol 2005 Dec;91(6):1468-73. 
10. Alonso-Vega C, Billot C, Torrico F. Achievements and challenges upon the 
implementation of a program for national control of congenital Chagas in Bolivia: results 
2004-2009. PLoS Negl Trop Dis 2013;7(7):e2304. 
11. Blanco SB, Segura EL, Cura EN, et al. Congenital transmission of Trypanosoma cruzi: 
an operational outline for detecting and treating infected infants in north-western 
Argentina. Trop Med Int Health 2000 Apr;5(4):293-301. 
12. Torrico F, Alonso-Vega C, Suarez E, et al. Maternal Trypanosoma cruzi infection, 
pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected 
newborns in Bolivia. Am J Trop Med Hyg 2004 Feb;70(2):201-9. 
13. Bittencourt AL. Congenital Chagas disease. Am J Dis Child 1976 Jan;130(1):97-103. 
14. Torrico MC, Solano M, Guzman JM, et al. [Estimation of the parasitemia in 
Trypanosoma cruzi human infection: high parasitemias are associated with severe and 
fatal congenital Chagas disease]. Rev Soc Bras Med Trop 2005;38 Suppl 2:58-61. 
15. Wincker P, Britto C, Pereira JB, Cardoso MA, Oelemann W, Morel CM. Use of a 
simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood 
samples from chronic chagasic patients in a rural endemic area. Am J Trop Med Hyg 
1994 Dec;51(6):771-7. 
16. Piron M, Fisa R, Casamitjana N, et al. Development of a real-time PCR assay for 
Trypanosoma cruzi detection in blood samples. Acta Trop 2007 Sep;103(3):195-200. 
17. Umezawa ES, Nascimento MS, Kesper N, Jr., et al. Immunoblot assay using excreted-
secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic 
Chagas' disease. J Clin Microbiol 1996 Sep;34(9):2143-7. 
17 
 
18. Dias JC. Evolution of Chagas disease screening programs and control programs: 
historical perspective. Global heart 2015 Sep;10(3):193-202. 
19. Gurtler RE. Sustainability of vector control strategies in the Gran Chaco Region: current 
challenges and possible approaches. Mem Inst Oswaldo Cruz 2009 Jul;104 Suppl 1:52-9. 
20. Reithinger R, Tarleton RL, Urbina JA, Kitron U, Gurtler RE. Eliminating Chagas 
disease: challenges and a roadmap. Bmj 2009;338:b1283. 
21. Bua J, Volta BJ, Velazquez EB, Ruiz AM, Rissio AM, Cardoni RL. Vertical transmission 
of Trypanosoma cruzi infection: quantification of parasite burden in mothers and their 
children by parasite DNA amplification. Trans R Soc Trop Med Hyg 2012 
Oct;106(10):623-8. 
22. Montes-Rincon LM, Galaviz-Silva L, Gonzalez-Bravo FE, Molina-Garza ZJ. 
Trypanosoma cruzi seroprevalence in pregnant women and screening by PCR and 
microhaematocrit in newborns from Guanajuato, Mexico. Acta Trop 2016 Dec;164:100-
6. 
23. Bisio M, Seidenstein ME, Burgos JM, et al. Urbanization of congenital transmission of 
Trypanosoma cruzi: prospective polymerase chain reaction study in pregnancy. Trans R 
Soc Trop Med Hyg 2011 Oct;105(10):543-9. 
24. Salas Clavijo NA, Postigo JR, Schneider D, Santalla JA, Brutus L, Chippaux JP. 
Prevalence of Chagas disease in pregnant women and incidence of congenital 
transmission in Santa Cruz de la Sierra, Bolivia. Acta Trop 2012 Oct;124(1):87-91. 
25. Bua J, Volta BJ, Perrone AE, et al. How to improve the early diagnosis of Trypanosoma 
cruzi infection: relationship between validated conventional diagnosis and quantitative 
DNA amplification in congenitally infected children. PLoS Negl Trop Dis 
2013;7(10):e2476. 
26. Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas' 
disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob 
Chemother 2003 Sep;52(3):441-9. 
27. Cormick G, Ciganda A, Cafferata ML, et al. Text message interventions for follow up of 
infants born to mothers positive for Chagas disease in Tucuman, Argentina: a feasibility 
study. BMC research notes 2015 Sep 29;8:508. 
28. Shah V, Ferrufino L, Gilman RH, et al. Field evaluation of the InBios Chagas Detect Plus 
rapid test in serum and whole blood specimens in Bolivia. Clinical and vaccine 
immunology : CVI 2014 Oct 1. 
29. Castro-Sesquen YE, Gilman RH, Galdos-Cardenas G, et al. Use of a novel Chagas urine 
nanoparticle test (chunap) for diagnosis of congenital Chagas disease. PLoS Negl Trop 
Dis 2014 Oct;8(10):e3211. 
 
18 
 
Table 1. Diagnostic test results for 38 infants with congenital Trypanosoma cruzi infection.  
 
 
Conventional diagnosis qPCR in blood or tissue IgM TESA-blot Age (months) at 
Infant Test Age
 
0m Umb tissue 1m 0m 1m First positive test Treatment 
1 Serology 9 - - - - - 6 9 
2 Micromethod 1 + + + + - 0 1 
3 Serology 9 + + + - + 0 9 
4 Serology 9 NS NS + NS + 1 9 
5 Serology 9 - NS - - - 9 Lost to follow-up 
6 Micromethod 3 - + + - - 0 3 
7 Micromethod 1 + + + + - 0 1 
8 Serology 11 + + NS + NS 0 11 
9 Serology 9 + + NS - NS 0 Lost to follow-up 
10 Micromethod 1.5 NS NS + NS - 1 1.5 
11 Missed 
 
+ + NS + NS 0 Lost to follow-up 
12 Serology 6 - - - - - 6 6 
13A Micromethod 0 + + PT + + (PT) 0 <1 
13B Micromethod 0 + + PT + + (PT) 0 <1 
14 Micromethod 1 + + PT + + (PT) 0 1 
15 Serology 6 + + + + + 0 11 
16 Missed 
 
+ BL NS + NS 0 Lost to follow-up 
17 Serology 6 - - - - - 6 6 
18 Missed 
 
+ + NS + NS 0 Lost to follow-up 
19 Serology 6 + + + + + 0 6 
20 Serology 9 + + + + + 0 9 
21 Serology 11 - - - - - 11 11 
22 Serology 9 - - + - + 1 9 
23 Missed 
 
- - + + + 0 Lost to follow-up 
24A Serology 6 + - + + - 0 6 
24B Micromethod 0 + + PT + -  (PT) 0 <1 
25A Serology 6 - + + - + 0 6 
25B Serology 6 BL + + + NS 0 6 
26 Serology 6 - - - - - 6 6 
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27 Serology 9 + + + + - 0 9 
28 Micromethod 1 + + + - + 0 1 
29 Micromethod 0 + + PT + + (PT) 0 <1 
30 Serology 6 + + NS + + 0 6 
31 Serology 6 + - + - + 0 6 
32 Micromethod 1 + + NS + - 0 1 
33 Serology 9 - NS + - - 1 9 
34 Micromethod 2 + - + - + 0 2 
35 Micromethod 0 + + PT + + (PT) 0 <1 
 
NS = no specimen; PT = specimen collected after initiation of treatment; BL = borderline  
Table 2. Performance of diagnostic tests for congenital Chagas disease in specimens from infants of infected mothers. 
 
 
Micromethod IgM TESA-blot 
 Cord blood 1 month blood
1 
Cumulative Cord blood 1 month blood
1 
Cumulative 
Infant status Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos 
  Uninfected 431 0 301 0 445 0 377 2 275 2 399 4 
  Infected 30 6 20 7 25 13 15 21 14 12 10 28 
Performance % [95% CI]     
 
      
 
      
 
  
  Sensitivity  16.7 [6, 33] 25.9 [11, 46] 34.2 [20, 51] 58.3 [41, 75] 46.2 [27, 67] 73.7 [57, 87] 
  Specificity 100 [99, 100] 100 [99, 100] 100 [99, 100] 99.5 [98, 100] 99.3 [97, 100] 99.0 [97, 100] 
  PPV 100 [54, 100] 100 [59, 100] 100 [75,100] 91.3 [72, 99] 85.7 [57, 98] 87.5 [71, 96] 
  NPV 93.5 [91, 96] 93.8 [91, 96] 94.7 [92, 97] 96.2 [94, 98] 95.2 [92, 97] 97.6 [96, 99] 
             
 
Quantitative PCR 
     Cord blood Umbilical tissue 1 month blood
1 
Cumulative 
    Infant status Neg Pos Neg Pos Neg Pos Neg Pos 
      Uninfected 390 10 81 1 257 0 411 11 
      Infected 12 24 11 23 6 19 6 32 
    Performance % [95% CI]     
  
    
 
  
      Sensitivity  66.7 [49, 81] 67.6 [49, 83] 76.0 [55, 91] 84.2 [69, 94] 
      Specificity 97.5 [95, 99] 98.8 [93, 100] 100 [99, 100] 97.4 [95, 99] 
      PPV 70.6 [53, 85] 95.8 [79, 100] 100 [82, 100] 74.4 [59, 86] 
      NPV 97.0 [95, 98] 88.0 [80, 94] 97.7 [95, 99] 98.6 [97, 99] 
    
             
 
Conventional serology at 6 months or older 
   IHA >=16 at 6m IHA >=128 at 6m EIA at 6m IHA >=16 at 9m EIA at 9m 
  Infant status Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos 
    Uninfected 203 50 245 8 159 49 166 7 163 3 
    Infected 1 14 6 9 0 14 0 12 0 12 
  Performance % [95% CI]                     
    Sensitivity  93.3 [68, 100] 60.0 [32, 84] 100 [77, 100] 100 [74, 100] 100 [74, 100] 
    Specificity 80.2 [75, 85] 96.8 [94, 99] 76.4 [70, 82] 96.0 [92,  98] 98.2 [95, 100] 
    PPV 21.9 [13, 34] 52.9 [28, 77] 22.2 [13, 34] 63.2 [38, 84] 80.0 [52, 96] 
    NPV 99.5 [97, 100] 97.6 [95, 99] 100 [98, 100] 100 [98, 100] 100 [98, 100] 
  PPV, Positive predictive value; NPV, negative predictive value 
21 
 
1
Six infants treated before 1 month of age excluded from 1 month specimen analyses. 
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Table 3. Clinical outcomes among singleton infants in the congenital Chagas disease cohort study, Santa Cruz and Camiri, 
Bolivia. 
 
 M+B+ M+B- M-B-   P value   
Characteristic Infected mother - 
infected infant 
(N=32)
1 
Infected mother - 
uninfected infant 
(N=252)
2 
Uninfected mother 
– uninfected infant 
(N=1360)
3 
M+B+ vs 
M+B- 
M+B+ vs 
M-B- 
M+B- vs 
M-B- 
Maternal characteristics       
Primiparous
 
7 (21.9) 48 (19.7) 494 (36.3) NS NS <0.001 
Maternal age (median [IQR])
 
23.5 [19.6, 28.1] 26.9 [22.0, 34.2] 22.7 [19.0, 28.9] <0.01 NS <0.001 
Cesarean section
 
19 (59.4) 121 (49.6) 613 (45.1) NS NS NS 
PROM
 
4 (12.5) 16 (6.7) 196 (14.8) NS NS <0.001 
Infant characteristics       
Female sex
 
26 (68.4) 114 (46.7) 658 (48.5) <0.05 NS NS 
Birth weight (median [IQR])
 
2980 [2500, 3525] 3300 [3070, 3650] 3300 [2960, 3600] <0.05 <0.05 NS 
Birth weight <2500 grams
 
7 (21.9) 12 (5.0) 107 (7.9) <0.01 <0.05 NS 
1-minute Apgar score <7 1 (3.1) 11 (4.5) 41 (3.0) NS NS NS 
5-minute Apgar score <7 0 (0) 1 (0.4) 4 (0.3) NS NS NS 
Premature by exam
 
6 (18.8) 11 (4.6) 90 (6.6) <0.01 <0.05 NS 
Hospitalized at birth 5 (15.6) 16 (6.7) 131 (9.7) NS NS NS 
Respiratory distress  4 (12.5) 10 (4.2) 119 (8.8) 0.07 NS <0.05 
NS, non-significant; IQR, interquartile range; PROM, premature rupture of membranes 
 
1
Excludes 3 sets of twins, all concordantly infected 
2
Excludes 4 sets of twins, 174 infants with no specimen at 6 or 9 months and 23 infants whose final serology was inconclusive 
3
Excludes 15 sets of twins 
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Table 4. Characteristics of T. cruzi-infected infants with and without clinical signs consistent with congenital Chagas disease.  
 
Characteristic 
Infants with clinical signs 
(N=11) 
Infants without clinical 
signs (N=27) 
P value 
Median [IQR] maternal age 20.8 [16.3,23.0] 25.5 [22.0, 30.9] 0.04 
Median [IQR] parity 2 [1,3] 3 [2,4] 0.04 
    
Cord blood specimen    
  Micromethod positive  4/11 (36.4) 2/25 (8.0) 0.06 
  qPCR positive 9/11 (81.8) 15/24 (62.5) 0.44 
  Median [IQR] parasites/mL  89,263 [5.4, 571552] 37.9 [0, 10,175] 0.04 
  IgM TESA-blot positive 8/11 (72.7) 13/25 (52.0) 0.30 
    
Umbilical cord tissue    
  qPCR positive 9/11 (81.8) 14/22 (63.4) 0.43 
  Median [IQR] parasites/mL  859,119 [2133,>10
6
] 5.9 [0, 948,591] 0.06 
    
1 month blood specimen
1 
   
  Micromethod positive 3/7 (42.9) 4/20 (20) 0.33 
  qPCR positive 4/6 (66.7) 15/19 (79.0) 0.61 
  Median [IQR] parasites/mL  37,517 [0, 90,855] 342 [1.1, 8720] 0.39 
  IgM TESA-blot positive
 
2/7 (28.6) 10/19 (52.6) 0.39 
    
Cumulative 0 and 1 month results   
  Micromethod positive 7/11 (63.6) 6/27 (22.2) 0.03 
  qPCR positive 9/11 (81.8) 23/27 (85.2) 1.00 
  IgM TESA-blot positive 9/11 (81.8) 19/26 (73.1) 0.69 
 
1
Six infants (4 with and 2 without clinical signs) treated before 1 month of age excluded from these analyses. 
 
